Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis

被引:0
作者
Mitzy Kennis
Lotte Gerritsen
Marije van Dalen
Alishia Williams
Pim Cuijpers
Claudi Bockting
机构
[1] Utrecht University,Department of Clinical Psychology
[2] the University of New South Wales,School of Psychology, Faculty of Science
[3] Vrije Universiteit Amsterdam,Department of Clinical, Neuro and Developmental Psychology, Amsterdam Public Health research institute
[4] Amsterdam University Medical Centers,Department of Psychiatry
[5] location AMC,Institute for Advanced Study
[6] University of Amsterdam,undefined
[7] University of Amsterdam,undefined
来源
Molecular Psychiatry | 2020年 / 25卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Leading biological hypotheses propose that biological changes may underlie major depressive disorder onset and relapse/recurrence. Here, we investigate if there is prospective evidence for biomarkers derived from leading theories. We focus on neuroimaging, gastrointestinal factors, immunology, neurotrophic factors, neurotransmitters, hormones, and oxidative stress. Searches were performed in Pubmed, Embase and PsychInfo for articles published up to 06/2019. References and citations of included articles were screened to identify additional articles. Inclusion criteria were having an MDD diagnosis as outcome, a biomarker as predictor, and prospective design search terms were formulated accordingly. PRISMA guidelines were applied. Meta-analyses were performed using a random effect model when three or more comparable studies were identified, using a random effect model. Our search resulted in 67,464 articles, of which 75 prospective articles were identified on: Neuroimaging (N = 24), Gastrointestinal factors (N = 1), Immunology (N = 8), Neurotrophic (N = 2), Neurotransmitters (N = 1), Hormones (N = 39), Oxidative stress (N = 1). Meta-analyses on brain volumes and immunology markers were not significant. Only cortisol (N = 19, OR = 1.294, p = 0.024) showed a predictive effect on onset/relapse/recurrence of MDD, but not on time until MDD onset/relapse/recurrence. However, this effect disappeared when studies including participants with a baseline clinical diagnosis were removed from the analyses. Other studies were too heterogeneous to compare. Thus, there is a lack of evidence for leading biological theories for onset and maintenance of depression. Only cortisol was identified as potential predictor for MDD, but results are influenced by the disease state. High-quality (prospective) studies on MDD are needed to disentangle the etiology and maintenance of MDD.
引用
收藏
页码:321 / 338
页数:17
相关论文
共 540 条
[1]  
Kessler RC(2005)Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication Arch Gen Psychiatry 62 617-27
[2]  
Chiu WT(2007)Depression, chronic diseases, and decrements in health: results from the World Health Surveys Lancet 370 851-8
[3]  
Demler O(2013)Recurrence of major depressive disorder across different treatment settings: results from the NESDA study J Affect Disord 147 225-31
[4]  
Merikangas KR(2010)How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment Psychol Med 40 899-909
[5]  
Walters EE(1999)Recurrence after recovery from major depressive disorder during 15 years of observational follow-up Am J Psychiatry 156 1000-6
[6]  
Moussavi S(2018)Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis Lancet 391 1357-66
[7]  
Chatterji S(2012)Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review Neuropsychopharmacology 37 851-64
[8]  
Verdes E(2010)Linking molecules to mood: new insight into the biology of depression Am J Psychiatry 167 1305-20
[9]  
Tandon A(2002)Neurobiology of depression Neuron 34 13-25
[10]  
Patel V(2008)Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression Neuropsychopharmacology 33 368-77